<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04089982</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103506</org_study_id>
    <nct_id>NCT04089982</nct_id>
  </id_info>
  <brief_title>Varenicline Light Smoking Pilot</brief_title>
  <official_title>Pilot Study on Varenicline in Light and Intermittent Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to assess varenicline vs. placebo for its effect on decreasing cue&#xD;
      reactivity in light and intermittent smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of randomization to receive either varenicline or placebo over 6 weeks&#xD;
      and include 5 study visits. Participants are offered an optional additional 6 weeks of active&#xD;
      varenicline. Cue reactivity will be assessed in both a lab-based setting (viewing series of&#xD;
      images and rating cravings) and in a real-world setting (text-based daily interaction).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2-arm randomized, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Self-Reported Craving Level Via Lab-Based Cue Reactivity</measure>
    <time_frame>Baseline, Visit 4 (week 6)</time_frame>
    <description>Participants were asked to self-report craving level to smoke on a scale of 1-10 with 1 corresponding to no craving and 10 corresponding to intense craving. Self-reported craving level was requested following presentation of multiple images on a screen over a 20 minute period. Four types of images were presented - neutral affect, negative affect, smoking and social images.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Self-Reported Craving Level Via Real-World Cue Reactivity</measure>
    <time_frame>Baseline, Visit 4 (week 6)</time_frame>
    <description>Craving level in &quot;real world&quot; situations was assessed through electronic momentary assessment (EMA). Participants were instructed to send a text to the study team each time they experienced craving to smoke a cigarette. Self-report craving level to smoke was reported on a scale of 1-10 with 1 corresponding to no craving and 10 corresponding to intense craving.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Smoking</measure>
    <time_frame>Screening visit, Visit 4 (week 6)</time_frame>
    <description>7-day point prevalence smoking abstinence. This will be measured through self-reported daily smoking diaries and daily text messaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>Screening visit, Visit 4 (week 6)</time_frame>
    <description>Medication adherence is measured by composite self-reported diaries and daily text messaging responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Tolerance by Self-Reported Side Effects</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Self-reported side effects (open ended survey questions) with a ranking scale of 1-2 (mild), 3-5 (moderate), and 6-7 (severe). Any side effect 3 or greater will be reviewed by a study medical provider.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Smoking Abstinence</measure>
    <time_frame>Screening visit, Visit 4 (week 6)</time_frame>
    <description>7-day point prevalence smoking abstinence confirmed by CO &lt;7ppm. This will be measured through biochemical confirmation (CO breath test).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Smoking Behaviors</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Chantix</description>
    <arm_group_label>Varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or above&#xD;
&#xD;
          2. Daily smoker using 10 or less cigarettes per day but a minimum of at least 1&#xD;
             cigarettes per week or 4 cigs/month.&#xD;
&#xD;
          3. Must be able to make it through a 24-hour period without nicotine withdrawal symptoms&#xD;
             (specifically does not have new onset of irritability, headaches, insomnia, or intense&#xD;
             cravings).&#xD;
&#xD;
          4. Willing to quit smoking in the next 30 days&#xD;
&#xD;
          5. Is able to provide written informed consent (in English) to participate in the study&#xD;
             and is able to read/understand the procedures and study requirements.&#xD;
&#xD;
          6. Is willing to voluntarily sign and date an informed consent form that is approved by&#xD;
             an institutional review board before the conduct of any study procedure.&#xD;
&#xD;
          7. If female and of childbearing potential, is willing to use medically acceptable&#xD;
             contraceptive measures for the duration of the study. Acceptable methods of&#xD;
             contraception include (1) surgical sterilization (such as tubal ligation or&#xD;
             hysterectomy, (2) approved hormonal contraceptives (such as birth control pills,&#xD;
             patches, implants or injections), (3) barrier methods (such as condom or diaphragm)&#xD;
             used with a spermicide, or (4) an intrauterine device (IUD). Contraceptive measures&#xD;
             such as rhythm method or Plan Bâ„¢, sold for emergency use after unprotected sex, are&#xD;
             not acceptable methods for routine use.&#xD;
&#xD;
          8. Have access to a cell phone that can send and receive SMS text messages.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of a smoking cessation medication (e.g. nicotine replacement, varenicline,&#xD;
             bupropion) in last 30 days.&#xD;
&#xD;
          2. Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless&#xD;
             tobacco) in the last 30 days&#xD;
&#xD;
          3. Answer &gt; 0 on suicidality question of Patient Health Questionnaire (PHQ-9) Depression&#xD;
             Scale&#xD;
&#xD;
          4. Active alcohol use disorder or hazardous drinking. This will be screened with the&#xD;
             AUDIT-C, and positive scores (4 or greater for men and 3 or greater for women)54,55&#xD;
             will result in study clinician assessment and discretion.&#xD;
&#xD;
          5. Use of illicit drugs in the last month (marijuana, cocaine, opiates, benzodiazepines,&#xD;
             and/or methamphetamine)&#xD;
&#xD;
          6. Severe symptomatic depression and or anxiety (study medical provider discretion)&#xD;
&#xD;
          7. Diagnosis of bipolar disorder, schizophrenia, PTSD and or adult ADHD (study medical&#xD;
             provider discretion)&#xD;
&#xD;
          8. Chronic medical illness including diabetes with the use of insulin, Hemoglobin A1c &gt; 7&#xD;
             (study medical provider discretion), heart disease diagnosed by angiogram, or COPD&#xD;
             diagnosed by pulmonary function testing and requiring an oxygen supply&#xD;
&#xD;
          9. Specific medications (Appendix 1)&#xD;
&#xD;
         10. Abnormal finding on physical exam (study medical provider discretion)&#xD;
&#xD;
         11. Positive Urine Pregnancy Test (women of child bearing potential only; QuickVue Urine&#xD;
             Pregnancy)56&#xD;
&#xD;
         12. Positive Urine Toxicology-5 Screen (methamphetamine, cocaine, opiates,&#xD;
             benzodiazepines, THC)&#xD;
&#xD;
         13. Unstable hypertension (Blood pressure &gt; 160/100)&#xD;
&#xD;
         14. Renal failure with active or pending hemodialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <results_first_submitted>February 24, 2021</results_first_submitted>
  <results_first_submitted_qc>May 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT04089982/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline</title>
          <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo oral tablet: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline</title>
          <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo oral tablet: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="7.1"/>
                    <measurement group_id="B2" value="42.6" spread="12.7"/>
                    <measurement group_id="B3" value="38.4" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Self-Reported Craving Level Via Lab-Based Cue Reactivity</title>
        <description>Participants were asked to self-report craving level to smoke on a scale of 1-10 with 1 corresponding to no craving and 10 corresponding to intense craving. Self-reported craving level was requested following presentation of multiple images on a screen over a 20 minute period. Four types of images were presented - neutral affect, negative affect, smoking and social images.</description>
        <time_frame>Baseline, Visit 4 (week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral tablet: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Self-Reported Craving Level Via Lab-Based Cue Reactivity</title>
          <description>Participants were asked to self-report craving level to smoke on a scale of 1-10 with 1 corresponding to no craving and 10 corresponding to intense craving. Self-reported craving level was requested following presentation of multiple images on a screen over a 20 minute period. Four types of images were presented - neutral affect, negative affect, smoking and social images.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="2.80"/>
                    <measurement group_id="O2" value="4.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="2.11"/>
                    <measurement group_id="O2" value="2.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Self-Reported Craving Level Via Real-World Cue Reactivity</title>
        <description>Craving level in &quot;real world&quot; situations was assessed through electronic momentary assessment (EMA). Participants were instructed to send a text to the study team each time they experienced craving to smoke a cigarette. Self-report craving level to smoke was reported on a scale of 1-10 with 1 corresponding to no craving and 10 corresponding to intense craving.</description>
        <time_frame>Baseline, Visit 4 (week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral tablet: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Self-Reported Craving Level Via Real-World Cue Reactivity</title>
          <description>Craving level in &quot;real world&quot; situations was assessed through electronic momentary assessment (EMA). Participants were instructed to send a text to the study team each time they experienced craving to smoke a cigarette. Self-report craving level to smoke was reported on a scale of 1-10 with 1 corresponding to no craving and 10 corresponding to intense craving.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.15" spread="1.1"/>
                    <measurement group_id="O2" value="6.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.5"/>
                    <measurement group_id="O2" value="8" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Smoking</title>
        <description>7-day point prevalence smoking abstinence. This will be measured through self-reported daily smoking diaries and daily text messaging.</description>
        <time_frame>Screening visit, Visit 4 (week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral tablet: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Smoking</title>
          <description>7-day point prevalence smoking abstinence. This will be measured through self-reported daily smoking diaries and daily text messaging.</description>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="3.4"/>
                    <measurement group_id="O2" value="5.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.8"/>
                    <measurement group_id="O2" value="2.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence</title>
        <description>Medication adherence is measured by composite self-reported diaries and daily text messaging responses.</description>
        <time_frame>Screening visit, Visit 4 (week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral tablet: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>Medication adherence is measured by composite self-reported diaries and daily text messaging responses.</description>
          <units>Percent medication adherence</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" spread="0.08"/>
                    <measurement group_id="O2" value="90.3" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Tolerance by Self-Reported Side Effects</title>
        <description>Self-reported side effects (open ended survey questions) with a ranking scale of 1-2 (mild), 3-5 (moderate), and 6-7 (severe). Any side effect 3 or greater will be reviewed by a study medical provider.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral tablet: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Tolerance by Self-Reported Side Effects</title>
          <description>Self-reported side effects (open ended survey questions) with a ranking scale of 1-2 (mild), 3-5 (moderate), and 6-7 (severe). Any side effect 3 or greater will be reviewed by a study medical provider.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal/Vivid Dreams</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness/Lightheadedness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia/Trouble Sleeping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Smoking Abstinence</title>
        <description>7-day point prevalence smoking abstinence confirmed by CO &lt;7ppm. This will be measured through biochemical confirmation (CO breath test).</description>
        <time_frame>Screening visit, Visit 4 (week 6)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Varenicline</title>
            <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo oral tablet: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Smoking Abstinence</title>
          <description>7-day point prevalence smoking abstinence confirmed by CO &lt;7ppm. This will be measured through biochemical confirmation (CO breath test).</description>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="11.1"/>
                    <measurement group_id="O2" value="10.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.5"/>
                    <measurement group_id="O2" value="7.8" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline</title>
          <description>Varenicline BID&#xD;
Varenicline: Chantix</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo oral tablet: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma flare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Insomnia/Trouble Sleeping</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal/Vivid Dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James M. Davis, MD</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-5055</phone>
      <email>james.m.davis@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

